+ Watch ROSG
on My Watchlist
The Company is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs.
I'm really not sure why Rosetta Genomics is a public company. The share price has followed a steady downward trajectory since the IPO, and all the company has accomplished is the development of some microRNA cancer screening tests that no one is buying. It doesn't appear they have any other technology or any prospects for commercial success. With 5M in cash, it appears they may be entering a death spiral of dilutions and staff cuts. The only question here is if their platform is worth enough for someone like Alnylam or Isis to buy them out at a price substantially higher than their 9M cap. From that perspective, this is a very risky red thumb.
he who trades only solid companies and solid companies only will not be in the market for long.....
Fortunately it's free to write pitch replies. You've spent nothing to spew complete and utter nonsense.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions